...
首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Distinguishing Clear Cell Renal Cell Carcinoma, Retroperitoneal Paraganglioma, and Adrenal Cortical Lesions on Limited Biopsy Material Utility of Immunohistochemical Markers
【24h】

Distinguishing Clear Cell Renal Cell Carcinoma, Retroperitoneal Paraganglioma, and Adrenal Cortical Lesions on Limited Biopsy Material Utility of Immunohistochemical Markers

机译:区分透明细胞肾细胞癌,腹膜后副神经节瘤和肾上腺皮质病变对免疫组织化学标记物的有限活检物质效用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract: Retroperitoneal recurrence of clear cell renal cell carcinoma (CCRCC) after surgical resection is often investigated by needle biopsy and frequently requires immunohisto-chemistry to distinguish from other lesions with similar histology. This study explores the diagnostic utility of a panel of immunohistochemical markers and emphasizes potential pitfalls in dealing with this differential diagnosis. A tissue microarray with 1 mm tissue cores was constructed to include 21 CCRCC, 19 adrenocortical lesions, and 15 retroperitoneal or mediastinal paragangliomas. Triplicate cores were used for each case. The tissue microarray was then immunostained with epithelial, RCC, adrenocortical, and neuroendocrine markers. Pancytokeratins AE1/3, CAM5.2, and epithelial membrane antigen were positive in 52.4%, 66.7%, and 61.9% of CCRCC cases. Three (14.2%) CCRCC cases were negative for all 3 epithelial markers.,.AEl/3 and epithelial membrane antigen were negative in all adrenocortical lesions and paraganglioma cases, whereas CAM5.2 was positive in 78.9% of adrenocortical lesions and 6.7% of paragangliomas. RCC markers, including RCC Ag, CA9, and CD10, were positive in 76.2%, 85.7%, and 100% of CCRCC cases and were negative in all adrenocortical lesions and paragangliomas. Calretinin and Melan-A were positive in 100% and 94.7% of adrenal, 0% and 14.3% of CCRCC, and 26.7% and 26.7% of paragangliomas. Epithelial markers may be entirely negative in CCRCC, whereas pancy-tokeratin CAM5.2 is often positive in adrenocortical lesions. Furthermore, neuroendocrine markers are frequently positive in adrenocortical lesions. Therefore, a panel of, rather than single, epithelial, "CCRCC-specific," adrenocortical and neuroendocrine markers should be applied in the differential diagnosis of CCRCC, adrenocortical lesions, and paragangliomas.
机译:摘要:外科切除术后腹膜后透明细胞肾细胞癌(CCRCC)的腹膜复发经常通过针头活检进行检查,并且经常需要免疫组织化学来与其他具有相似组织学特征的病变区分开。这项研究探索了一组免疫组织化学标记物的诊断效用,并强调了在进行这种鉴别诊断时的潜在陷阱。构建具有1mm组织核心的组织微阵列,以包括21个CCRCC,19个肾上腺皮质病变和15个腹膜后或纵隔神经节旁瘤。在每种情况下均使用一式三份的核心。然后用上皮,RCC,肾上腺皮质和神经内分泌标记物对组织微阵列进行免疫染色。全细胞角蛋白AE1 / 3,CAM5.2和上皮膜抗原在CCRCC病例中分别占52.4%,66.7%和61.9%。 3例(14.2%)CCRCC病例的所有3种上皮标志物均为阴性..AEl / 3和上皮膜抗原在所有肾上腺皮质病变和副神经节瘤病例中均为阴性,而CAM5.2阳性在78.9%的肾上腺皮质病变和6.7%的肾上腺皮质病变中神经节瘤。 RCC标记,包括RCC Ag,CA9和CD10,在CCRCC病例中分别为76.2%,85.7%和100%为阳性,而在所有肾上腺皮质病变和神经节旁瘤中均为阴性。 Calretinin和Melan-A在100%和94.7%的肾上腺,0%和14.3%的CCRCC以及26.7%和26.7%的副神经节瘤中呈阳性。上皮标志物在CCRCC中可能完全阴性,而pant-tokeratin CAM5.2在肾上腺皮质病变中通常是阳性的。此外,神经内分泌标记物在肾上腺皮质病变中通常是阳性的。因此,应将一组而非单个的上皮“ CCRCC特异性”肾上腺皮质和神经内分泌标记物用于CCRCC,肾上腺皮质病变和神经节旁瘤的鉴别诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号